Vertex Pharmaceuticals Incorporated and Alpine Immune Sciences, Inc. have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share in cash, totaling approximately $4.9 billion. This strategic acquisition aims to leverage the scientific innovation of Alpine to create transformative medicines targeting serious diseases with high unmet need in specialty markets.